<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Arginine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Arginine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Arginine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11095" href="/d/html/11095.html" rel="external">see "Arginine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12797" href="/d/html/12797.html" rel="external">see "Arginine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F136608"><span class="drugH1">Brand Names: US</span>
<ul>
<li>R-Gene 10</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F136622"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F136609"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5699fdc-3fa5-42a8-a967-9427e9dd169b">Diagnostic aid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid (pituitary function): Note:</b> Dosing based on arginine hydrochloride product. IV: 30 g as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56052b19-ffc3-4a10-b5a1-c68dc1453a58">Hyperammonemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, acute (urea cycle disorders) (off-label use): Note: </b>
<b>Dosing based on arginine hydrochloride product </b>and on specific enzyme deficiency. Therapy should continue until ammonia levels are in normal range. If a loading dose is used, it should not be repeated. Arginine dose may be adjusted downward if patient becomes hypotensive and/or when the exact enzyme deficiency is identified. Administer concomitantly with sodium benzoate and sodium phenylacetate along with dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Argininosuccinate synthetase (ASS, <i>Citrullinemia</i>) or </i>
<i>Argininosuccinate lyase (ASL)</i>
<i>deficiency: </i>IV: Loading dose: 600 <b>mg/kg</b> followed by a continuous IV infusion of 600 <b>mg/kg</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> IV: Loading dose: 200 <b>mg/kg</b> followed by a continuous IV infusion of 200 <b>mg/kg</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 <b>mg/kg</b> followed by a continuous IV infusion of 600 <b>mg/kg</b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>); if ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 <b>mg/kg</b>/day.</p>
<p style="text-indent:-2em;margin-left:4em;">BSA-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Argininosuccinate synthetase (ASS, <i>Citrullinemia</i>) or </i>
<i>Argininosuccinate lyase (ASL)</i>
<i>deficiency: </i>IV: Loading dose: 12 <b>g</b>/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 <b>g</b>/<b>m<sup>2</sup></b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency: </i>IV: Loading dose: 4 <b>g</b>/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 <b>g</b>/<b>m<sup>2</sup></b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1dab86a-c49f-49d6-b4a7-a563c43468b9">Urea cycle disorders, chronic therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urea cycle disorders, chronic therapy (off-label use):</b> Oral: <b>Note: Dosing based on arginine free base powder product:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Argininosuccinate synthetase (ASS, Citrullinemia) or </i>
<i>Argininosuccinate lyase (ASL)</i>
<i>deficiency: </i>0.4 to 0.7 <b>g/kg/</b>day or 8.8 to 15.4 <b>g/m<sup>2</sup></b>/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21290785','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21290785','lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency:</i> 2.5 to 6 <b>g/m<sup>2</sup></b>/day in 3 or 4 divided doses (maximum: 6 g/day) has been recommended however, citrulline may be preferred therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982989','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982989','lexi-content-ref-NORD.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989972"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987305"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F136610"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F136617"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12797" href="/d/html/12797.html" rel="external">see "Arginine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56052b19-ffc3-4a10-b5a1-c68dc1453a58">Hyperammonemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, acute (urea cycle disorders):</b> Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administered concomitantly with sodium benzoate and sodium phenylacetate. Dosage based on specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. If patient already receiving arginine therapy, consider either a reduction in the loading dose or possible elimination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148549'])">Ref</a></span>); if a loading dose is used, it should not be repeated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>). <b>Note: Dosing based on arginine hydrochloride product.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> IV: Loading dose: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-NORD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NORD.1'])">Ref</a></span>). If ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">BSA-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 12 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 g/<b>m<sup>2</sup></b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-8794176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-8794176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) disorder:</i> IV: Loading dose: 4 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 g/<b>m<sup>2</sup></b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-8794176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148549','lexi-content-ref-8794176'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c30d66b-a075-45d3-8536-3439c965273a">Metabolic alkalosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic alkalosis:</b> Limited data available: Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Arginine hydrochloride is an alternative treatment for uncompensated metabolic alkalosis after sodium chloride and potassium chloride supplementation have been optimized; it should not be used as initial therapy for chloride supplementation. Each 1 g of arginine hydrochloride provides 4.75 mEq chloride. <b>Note: Dosing based on arginine hydrochloride product.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Arginine hydrochloride dose (mEq) = 0.5 x weight (kg) x [HCO<sub>3</sub>
<sup>-</sup> - 24] where HCO<sub>3</sub>
<sup>-</sup> = the patient's serum bicarbonate concentration in mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6764161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6764161'])">Ref</a></span>); give <sup>1</sup>/<sub>2</sub> to <sup>2</sup>/<sub>3</sub> of calculated dose and reevaluate.</p>
<p style="text-indent:-2em;margin-left:4em;">To correct hypochloremia: Arginine hydrochloride dose (mEq) = 0.2 x weight (kg) x [103 - Cl<sup>-</sup>] where Cl<sup>-</sup> = the patient's serum chloride concentration in mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6764161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6764161'])">Ref</a></span>); give <sup>1</sup>/<sub>2</sub> to <sup>2</sup>/<sub>3</sub> of calculated dose and reevaluate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ea3df63-fe53-49fc-a198-c26306cd55b6">Pituitary function test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pituitary function test: Note: Dosing based on arginine hydrochloride product:</b> Infants, Children, and Adolescents: IV: 0.5 <b>g</b>/kg over 30 minutes; maximum dose: 30 <b>g</b> dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1dab86a-c49f-49d6-b4a7-a563c43468b9">Urea cycle disorders, chronic therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urea cycle disorders, chronic therapy:</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Dose should be individualized based on patient response; doses may need to be increased by ~50% as part of a sick-day routine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148550'])">Ref</a></span>): <b>Note: Dosing based on arginine-free base powder product: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148549','lexi-content-ref-11148550','lexi-content-ref-8794176','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148549','lexi-content-ref-11148550','lexi-content-ref-8794176','lexi-content-ref-NORD.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Oral: 400 to 700 mg/kg/day in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: Oral: 8.8 to 15.4 g/<b>m<sup>2</sup></b>/day in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i>
<b>Note:</b> Citrulline may be preferred for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148549','lexi-content-ref-8794176','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148549','lexi-content-ref-8794176','lexi-content-ref-NORD.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Oral: 170 mg/kg/day in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: Oral: 3.8 g/<b>m<sup>2</sup></b>/day in 3 to 4 divided doses.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064912"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; use may lead to life-threatening hyperkalemia.</p></div>
<div class="block dohp drugH1Div" id="F51064913"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; use may lead to life-threatening hyperkalemia.</p></div>
<div class="block adr drugH1Div" id="F136585"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Diagnostic aid:</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Flushing, venous irritation</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache, numbness</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Decreased platelet count</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperammonemia, acute:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Hematologic abnormality (11%; including anemia [4%], disorder of hemostatic components of blood [&lt;3%], disorder of the lymphatic system, disseminated intravascular coagulation [3%], hemorrhage [&lt;3%], pancytopenia [&lt;3%], and thrombocytopenia [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (12%; including sepsis [&lt;3%], septic shock [&lt;3%], and urinary tract infection [3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Central nervous system dysfunction (22%; including absent reflexes [&lt;3%], ataxia [&lt;3%], brain edema [5%], cerebral atrophy [&lt;3%], cerebral hemorrhage [&lt;3%], cerebral infarction [&lt;3%], clonus [&lt;3%], coma [3%], decreased mental acuity [6%], encephalopathy [&lt;3%], impaired consciousness [&lt;3%], increased intracranial pressure [&lt;3%], paralysis [nerve: &lt;3%], seizure [6%], and tremor [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Respiratory system disorder (15%; including acute respiratory distress syndrome [&lt;3%], dyspnea [&lt;3%], hypercapnia [&lt;3%], hyperventilation [&lt;3%], Kussmaul respiration [&lt;3%], pulmonary edema [&lt;3%], pulmonary hemorrhage [&lt;3%], respiratory acidosis [&lt;3%], respiratory alkalosis [&lt;3%], respiratory distress [3%], respiratory failure [&lt;3%], tachypnea [&lt;3%], and variations in blood CO2 concentrations [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Cardiac disorder (9%; including acute cardiorespiratory failure [&lt;3%], bradycardia [&lt;3%], cardiogenic shock [&lt;3%], cardiomyopathy [&lt;3%], heart failure [&lt;3%], myocardial rupture [atrial: &lt;3%], and pericardial effusion [&lt;3%]), chest pain (&lt;3%), edema (&lt;3%), hypertension (&lt;3%), hypotension (4%), low cardiac output (&lt;3%), vascular disease (6%; including flushing [&lt;3%], thrombosis [&lt;3%], and venous thrombosis [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Dermatological disorder (6%; including alopecia [&lt;3%], pruritus [&lt;3%], skin blister [&lt;3%], skin rash [&lt;3%], and urticaria [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Acidosis (3%), alkalosis (&lt;3%), dehydration (&lt;3%), fluid retention (&lt;3%), hyperglycemia (7%), hypernatremia (&lt;3%), hypocalcemia (3%), hypoglycemia (&lt;3%), hypokalemia (7%), increased serum pH (&lt;3%), metabolic acidosis (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention (&lt;3%), cholestasis (&lt;3%), diarrhea (3%), gastrointestinal hemorrhage (&lt;3%), nausea (3%, vomiting (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatic artery stenosis (&lt;3%), hepatic failure (&lt;3%), hepatotoxicity (&lt;3%), jaundice (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site reaction (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (&lt;3%), cerebral herniation (&lt;3%), psychiatric disturbance (5%; including acute psychosis [&lt;3%], aggressive behavior [&lt;3%], agitation [3%], confusion [&lt;3%], and hallucination [&lt;3%]), subdural hematoma (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Tetany (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blindness (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Renal disease (4%; including anuria [&lt;3%], renal failure syndrome [&lt;3%], and urinary retention [&lt;3%])</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (5%), multi-organ failure (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hyperkalemia (Bushinsky 1978)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Esophagitis (Parra 2020), pancreatitis (Binet 2018)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Hematuria (Glibbery 2020)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis (Resnick 2002)</p></div>
<div class="block coi drugH1Div" id="F136597"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to arginine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F136582"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Irritant with vesicant-like properties. Due to the hypertonicity of the IV solution, administer via IV infusion only with a patent catheter placed within a patent vein. Extravasation has resulted in burn-like reactions and skin necrosis requiring surgical intervention. Excessive rates of infusion (eg, &lt;30 minutes) may result in local irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe reactions, including anaphylaxis, have been reported; if hypersensitivity occurs, discontinue and institute supportive treatment measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Excessive rates of infusion (eg, &lt;30 minutes) may result in flushing, nausea, or vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Use with caution in patients with electrolyte imbalance due to chloride content of product.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Arginine metabolism results in excretion of nitrogen-containing products. Use with caution in patients with renal impairment; decreased excretion may result in an increased amino acid or nitrogen burden.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Fatal overdose of arginine in pediatric patients has been reported. Exercise extreme caution when infusing arginine. Overdosage of arginine in children can also result in hyperchloremic metabolic acidosis or cerebral edema.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878334"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In neonates, infants, and children overdosage has resulted in hyperchloremic metabolic acidosis, cerebral edema, or possibly death; each 1 mEq chloride delivers 1 mEq hydrogen; monitor acid base balance closely, particularly in neonates. Arginine hydrochloride is metabolized to nitrogen-containing products for excretion; the temporary effect of a high nitrogen load on the kidneys should be evaluated. Accumulation of excess arginine may result in an overproduction of nitric oxide, leading to vasodilation and hypotension (Summar 2001). </p>
<p style="text-indent:0em;margin-top:2em;">Oral  products available in the US are often marketed as dietary supplements. When using these products, patients should take care to ensure that they are receiving pharmaceutical grade supplements of L-arginine and verify the formulation (free base vs arginine HCl). The National Urea Cycle Disorders Foundation cautions against using oral dietary supplements of arginine HCL (National Urea Cycles Disorder Foundation). </p></div>
<div class="block dosfc drugH1Div" id="F27747245"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">R-Gene 10 contains chloride 47.5 mEq per 100 mL</p></div>
<div class="block foc drugH1Div" id="F136592"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">R-Gene 10: 10% (300 mL) [latex free]</p></div>
<div class="block geq drugH1Div" id="F136578"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322999"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (R-Gene 10 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F136594"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer undiluted over 30 minutes. For doses &lt;30 g (&lt;300 mL), the manufacturer recommends transferring the dose to a separate container prior to administration. Prolongation of the infusion period may diminish the stimulus to the pituitary and nullify the test. In the treatment of hyperammonemia associated with urea cycle disorders (off-label use), administer loading dose over 90 to 120 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-NORD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-NORD.1'])">Ref</a></span>); maintenance infusion should not exceed 150 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; ensure proper catheter placement prior to and during infusion; avoid extravasation. Some recommend infusion through central access only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry cold compresses; initiate hyaluronidase antidote (if indicated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, powder:</b> Arginine free base: Take with meals and space doses evenly throughout the day. Oral products available in the US are often marketed as dietary supplements. When using these products, patients should take care to ensure that they are receiving pharmaceutical grade supplements of L-arginine and verify the formulation (free base vs arginine HCl). The National Urea Cycle Disorders Foundation cautions against using oral dietary supplements of arginine HCl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NUCDF.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NUCDF.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612261"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Arginine hydrochloride:</p>
<p style="text-indent:-2em;margin-left:4em;">Pituitary function test: Administer undiluted over 30 minutes. For doses &lt;30 g (&lt;300 mL), the manufacturer recommends transferring the dose to a separate container prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Hyperammonemia, acute (urea cycle disorders): May administer in combination with sodium benzoate and sodium phenylacetate injection; central line preferred. Administer loading dose over 90 to 120 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. Some recommend infusion through central access only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20301396','lexi-content-ref-11148543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20301396','lexi-content-ref-11148543'])">Ref</a></span>). If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; elevate extremity. Apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral, powder: Arginine-free base: Take with meals and space doses evenly throughout the day.</p></div>
<div class="block use drugH1Div" id="F136593"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic aid:</b> As an intravenous (IV) stimulant to the pituitary for the release of human growth hormone (hGH) in patients in whom the measurement of pituitary reserve for hGH can be of diagnostic usefulness. Used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism, and problems of growth and stature.</p></div>
<div class="block off-label drugH1Div" id="F45090537"><span class="drugH1">Use: Off-Label: Adult</span><p>Hyperammonemia (acute) associated with urea cycle disorders; Urea cycle disorders (chronic therapy)</p></div>
<div class="block mst drugH1Div" id="F7905819"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Food and Drug Administration (FDA) has identified several cases of fatal arginine overdose in children and has recommended that healthcare professionals always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298769"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F136586"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Arginine may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: Arginine may enhance the hypotensive effect of Herbal Products with Blood Pressure Lowering Effects. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F136600"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Teratogenic effects were not observed in animal studies; however, the manufacturer does not recommend use of arginine during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F136601"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Amino acids are present in breast milk, the amount following arginine administration is not known.</p></div>
<div class="block mop drugH1Div" id="F2572943"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Acid-base status (arterial or capillary blood gases), serum electrolytes (sodium, potassium, chloride, bicarbonate, phosphorous), BUN, glucose, plasma amino acids, ammonia, blood pressure (patients with hyperammonemia associated with urea cycle disorders [off-label use]). Monitor infusion site.</p></div>
<div class="block pha drugH1Div" id="F136581"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates pituitary release of growth hormone and prolactin through origins in the hypothalamus; patients with impaired pituitary function have lower or no increase in plasma concentrations of growth hormone after administration of arginine. In patients with urea cycle disorders, the formation of arginine is prohibited; therefore, exogenous administration of arginine is required.</p></div>
<div class="block phk drugH1Div" id="F136596"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~33 L/kg following a 30 g IV dose</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively metabolized in the liver and intestines (Cynober 2007)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~68%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: 42 ± 2 minutes following a 30 g IV dose; exhibits nonlinear, dose-dependent elimination (Tangphao 1999)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~2 hours; IV: 22 to 30 minutes (Bode-Boger 1998; Tangphao 1999)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (16% during the first 90 minutes; biphasic elimination) (Tangphao 1999)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038532"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">L arginine | Sargenor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arginina</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">L-arginine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Argix | Forvital | Reforgan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Arginine | Arginine hydrochloride and glucose</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arginin | Arginin hcl | Arginin vida | Echt vital L arginin | L arginin | L arginin hcl | La-L-Arginin | Perfusia | Sana arginin | Sanaponte l arginin | Vegavero l arginin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Asparten</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Argimax | Argisan | L arginiine hcl | L-arginin hcl | L-arginine HCL | Super strength L arginine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arginine veyron | Sargenor</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dynamisan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Argihope | Arginitric</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bioarginina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">L arginine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Argi u | Arginine ajinomoto</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Tivortin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alginase | GC Arginine | Hepawon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Argivial | L-arginine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">L arginin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Swanson l-arginine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Arginitric | L-arginine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">L-arginine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Clinicians L Arginine | Clinicians L-Arginine | L-arginine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dynamisan | L-arginine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Nature's bounty l arginine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Arginina</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Arginine HCL | Arginine hcl | L arginine | L-arginine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Asparten | Pan astenico | Sargenor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tivortin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">L arginine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">California gold nutrition l-arginine | Vistra L Arginine | Vitamate L arginine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Arginine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Doppelherz aktiv l-arjinin | Solgar L Arginine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">L-arginine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Angio betargin | Argilife | Libra | Sargin | Solargin | Tivortin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Tivortin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">A T Arginin | Aldermis | Argistad | Inopantine | Morganin | Siqueira | Tanagimax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arginine | Essentials l arginine | L-arginine | Sperm-Aid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20301396">
<a name="20301396"></a>Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea cycle disorders overview. In: Adam MP, Ardinger HH, Pagon RA, et al editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2017. <a href="http://www.ncbi.nlm.nih.gov/books/NBK1217/" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK1217/</a>. Published April 29, 2003. Updated June 22, 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/20301396/pubmed" id="20301396" target="_blank">20301396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12006956">
<a name="12006956"></a>Amin HJ, Zamora SA, McMillan DD, et al, "Arginine Supplementation Prevents Necrotizing Enterocolitis in the Premature Infant," <i>J Pediatr</i>, 2002, 140(4):425-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/12006956/pubmed" id="12006956" target="_blank">12006956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ammonul.1">
<a name="Ammonul.1"></a>Ammonul (sodium phenylacetate and sodium benzoate) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148549">
<a name="11148549"></a>Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. <i>J Pediatr</i>. 2001;138(1 Suppl):S46-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148549/pubmed" id="11148549" target="_blank">11148549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148550">
<a name="11148550"></a>Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S56-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148550/pubmed" id="11148550" target="_blank">11148550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29680982">
<a name="29680982"></a>Binet Q, Dufour I, Agneessens E, et al. The second case of a young man with L-arginine-induced acute pancreatitis. <i>Clin J Gastroenterol</i>. 2018;11(5):424-427. doi:10.1007/s12328-018-0862-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/29680982/pubmed" id="29680982" target="_blank">29680982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9833603">
<a name="9833603"></a>Bode-Boger SM, Boger RH, Galland A, Tsikas D, Frolich JC. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. <i>Br J Clin Pharmacol</i>. 1998;46(5):489-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/9833603/pubmed" id="9833603" target="_blank">9833603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8794176">
<a name="8794176"></a>Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. <i>Adv Pediatr</i>. 1996;43:127-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/8794176/pubmed" id="8794176" target="_blank">8794176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-717931">
<a name="717931"></a>Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. <i>Ann Intern Med</i>. 1978;89(5 Pt 1):632-634. doi:10.7326/0003-4819-89-5-632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/717931/pubmed" id="717931" target="_blank">717931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17513441">
<a name="17513441"></a>Cynober L. Pharmacokinetics of arginine and related amino acids. <i>J Nutr</i>. 2007;137(6 Suppl 2):1646S-1649S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/17513441/pubmed" id="17513441" target="_blank">17513441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17538087">
<a name="17538087"></a>Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. <i>N Engl J Med</i>. 2007;356(22):2282-2292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/17538087/pubmed" id="17538087" target="_blank">17538087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32547619">
<a name="32547619"></a>Glibbery M, Fleming A, Chanchlani R, et al. Myalgia and hematuria in association with clonidine and arginine administration for growth hormone stimulation tests. <i>Case Rep Med</i>. 2020;2020:4827072. doi:10.1155/2020/4827072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/32547619/pubmed" id="32547619" target="_blank">32547619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982989">
<a name="30982989"></a>Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. <i>J Inherit Metab Dis</i>. 2019;42(6):1192-1230. doi:10.1002/jimd.12100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/30982989/pubmed" id="30982989" target="_blank">30982989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12069536">
<a name="12069536"></a>Leonard JV, Morris AA. Urea cycle disorders. <i>Semin Neonatol</i>. 2002;7(1):27-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/12069536/pubmed" id="12069536" target="_blank">12069536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6764161">
<a name="6764161"></a>Martin WJ and Matzke GR, "Treating Severe Metabolic Alkalosis," <i>Clin Pharm</i>, 1982, 1(1):42-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/6764161/pubmed" id="6764161" target="_blank">6764161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21290785">
<a name="21290785"></a>Nagamani SCS, Erez A, Lee B. Argininosuccinate lyase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2017. Published February 3, 2011. Updated March 2019. <a href="http://www.ncbi.nlm.nih.gov/books/NBK51784/" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK51784/</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/21290785/pubmed" id="21290785" target="_blank">21290785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NORD.1">
<a name="NORD.1"></a>National Organization for Rare Disorders (NORD). The Physician's Guide to Urea Cycle Disorders. Danbury, CT: National Organization for Rare Disorders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NUCDF.1">
<a name="NUCDF.1"></a>National Urea Cycle Disorders Foundation. Available at http://www.nucdf.org/medical_information.htm.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115583">
<a name="32115583"></a>Parra PR, González-Cruz MÁ, Ferreiro-Marin A, Casaubón-Garcín PR. L-arginine-induced esophagitis, report of six cases. <i>Bol Med Hosp Infant Mex</i>. 2020;77(1):38-41. doi:10.24875/BMHIM.19000109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/32115583/pubmed" id="32115583" target="_blank">32115583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11814282">
<a name="11814282"></a>Resnick DJ, Softness B, Murphy AR, Aranoff GS, Levine LS. Case report of an anaphylactoid reaction to arginine. <i>Ann Allergy Asthma Immunol</i>. 2002;88(1):67-68. doi:10.1016/S1081-1206(10)63596-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11814282/pubmed" id="11814282" target="_blank">11814282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-R-Gene10.1">
<a name="R-Gene10.1"></a>R-Gene 10 (arginine) [prescribing information]. New York, NY: Pharmacia and Upjohn; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16391217">
<a name="16391217"></a>Schulman SP, Becker LC, Kass DA, L-Arginine Therapy in Acute Myocardial Infarction. The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial, <i>JAMA</i>, 2006, 295(1):58-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/16391217/pubmed" id="16391217" target="_blank">16391217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17636753">
<a name="17636753"></a>Shah P and Shah V, "Arginine Supplementation for Prevention of Necrotising Enterocolitis in Preterm Infants," <i>Cochrane Database Syst Rev</i>, 2007, (3):CD004339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/17636753/pubmed" id="17636753" target="_blank">17636753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148547">
<a name="11148547"></a>Summar M, “Current Strategies for the Management of Neonatal Urea Cycle Disorders,” <i>J Pediatr</i>, 2001, 138(1 Suppl):S30-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148547/pubmed" id="11148547" target="_blank">11148547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10215749">
<a name="10215749"></a>Tangphao O, Grossmann M, Chalon S, Hoffman BB, Blaschke TF. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. <i>Br J Clin Pharmacol</i>. 1999;47(3):261-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/10215749/pubmed" id="10215749" target="_blank">10215749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148543">
<a name="11148543"></a>Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148543/pubmed" id="11148543" target="_blank">11148543</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8883 Version 143.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
